BlackRock Investment Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

BlackRock Investment Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.13M	Sell	73,378 -1,275	-2%	-$16.6K	﹤0.01%	2623
2016 Q3	$971K	Buy	74,653 +20,520	+38%	+$272K	﹤0.01%	2693
2016 Q2	$753K	Buy	54,133 +11,135	+26%	+$164K	﹤0.01%	2829
2016 Q1	$652K	Buy	42,998 +1,211	+3%	+$18.5K	﹤0.01%	2768
2015 Q4	$793K	Buy	41,787 +223	+0.5%	+$4.26K	﹤0.01%	2754
2015 Q3	$790K	Sell	41,564 -821	-2%	-$20.5K	﹤0.01%	2770
2015 Q2	$1.09M	Buy	42,385 +42,169	+19,523%	+$1.2M	﹤0.01%	2704
2015 Q1	$7K	Hold	216	–	–	﹤0.01%	3780
2014 Q4	$8K	Sell	216 -37	-15%	-$883	﹤0.01%	3769
2014 Q3	$6K	Hold	253	–	–	﹤0.01%	3862
2014 Q2	$6K	Buy	+253	New	+$8.25K	﹤0.01%	3828

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

BlackRock Investment Management's PRTK Position: Q4 2016 in Review

BlackRock Investment Management reduced its Paratek Pharmaceuticals, Inc. (PRTK) stake by 1.7% in Q4 2016, selling an estimated $16.6K and leaving 73,378 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2623.

BlackRock Investment Management first reported a position in PRTK in Q2 2014 and has held it in 11 quarters since. 92 funds tracked by Wall St. Rank hold PRTK as of Q4 2016.

BlackRock Investment Management held 73,378 shares of Paratek Pharmaceuticals, Inc. worth $1.13M as of Q4 2016.
BlackRock Investment Management sold 1,275 Paratek Pharmaceuticals, Inc. shares in Q4 2016, an estimated $16.6K.
Paratek Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2623 holding.
BlackRock Investment Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2014 and has held it in 11 quarters since.
92 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.